Insilico Medicine Announces Industry's First Longevity Board to Accelerate AI-Driven Aging Research for Drug Discovery
Insilico Medicine has formed the industry's first Longevity Board to accelerate AI-driven aging research for drug discovery. The board is chaired by Andrew Adams, Group Vice President of Molecular Discovery at Eli Lilly and Company.
Insilico Medicine, a clinical-stage generative AI-driven biotechnology company, has formed the industry's first Longevity Board to accelerate AI-enabled aging research and drug discovery. The board is chaired by Andrew Adams, Group Vice President of Molecular Discovery at Eli Lilly and Company. The board will oversee research in life models, biomarkers of aging, and clinical development validating therapeutics on the hallmarks of aging. Insilico Medicine aims to develop therapeutics that target the fundamental biological processes of aging and extend healthspan. The company leverages generative AI to identify dual-purpose targets at the intersection of chronic disease and biological aging. The Longevity Board bridges the gap between cutting-edge longevity science and large-scale pharmaceutical development.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.